rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
A literature search using PubMed identified all the pertinent literature on the identification and utilization of the B-Raf(V600E) mutation in thyroid cancer.
|
20637346 |
2010 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
According to our experimental results, the panel including cf-DNA, SLC5A8 and SLC26A4 hypermethylation, and BRAF(V600E) analysis appears easy, reproducible, and non-invasive for the diagnosis on TC.
|
23931930 |
2013 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
|
27880942 |
2017 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72 (5.5%) colorectal cancers, 1/355 (0.3%) lung cancers, 2/6 thyroid cancers and 1/2 choriocarcinomas.
|
22012135 |
2012 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutational status in pediatric thyroid cancer.
|
24677749 |
2014 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF((V600E)) mutation is the most frequent genetic alteration in papillary thyroid carcinomas (PTCs) that are 80-90% of all thyroid cancers.
|
18310287 |
2008 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation, in both primary and metastatic thyroid cancers, is associated with a marked drop in thyroperoxidase (29-fold) and pendrin (20-fold) expression and a considerable increase (five-fold) in GLUT-1 expression.
|
17854396 |
2008 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(T1799A) mutation is the most prevalent genetic alteration in thyroid cancers and is specific for PTC, characteristics that make it the most potentially helpful genetic tool to improve the diagnostic accuracy of FNAB.
|
22504197 |
2012 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation and DNA methylation are useful markers to distinguish mali</span>gnant thyroid neoplasm from benign.
|
24588959 |
2014 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
|
25333496 |
2015 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
|
26456083 |
2016 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroid cancer and melanoma.
|
18462259 |
2009 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
|
24927793 |
2014 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
From September 2008 to December 2009, we performed routine analysis of the BRAF(V600E) mutation using thyroid cancer tissue from 424 patients who underwent thyroidectomy with cervical lymph node dissection.
|
21803329 |
2012 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic alterations occurring in thyroid cancer frequently affect the RAS/RAF/MEK/ERK-pathway such as the oncogenic, kinase-activating BRAF(V600E) mutation.
|
26892809 |
2016 |
rs113488022
|
|
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Given the strong genotype:phenotype correlation known to be present in thyroid cancer, the separation of BRAF(V600E)-like and RAS-like tumors has profound implications for its classification, especially the follicular variant of papillary carcinoma.
|
26569424 |
2016 |